US clearance lifts Glaxo-Wellcome

Friday 02 June 1995 23:02 BST

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

US clearance lifts Glaxo-Wellcome

Glaxo-Wellcome share price was buoyed yesterday by news that the company has received clearance by the United States Food and Drug Administration to market the tablet form of Imitrex, its migraine treatment. The drug has previously been available as an injection. The shares had been hit earlier in the day by press reports that a US broker had said the shares were overvalued.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

US clearance lifts Glaxo-Wellcome

Join our commenting forum

Thank you for registering